Bellevue Group AG lifted its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 111.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,870 shares of the biotechnology company’s stock after buying an additional 12,600 shares during the period. Bellevue Group AG owned 0.11% of Ligand Pharmaceuticals worth $3,239,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. First Hawaiian Bank grew its position in Ligand Pharmaceuticals by 22.7% in the 4th quarter. First Hawaiian Bank now owns 584 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 108 shares during the last quarter. Trillium Asset Management LLC grew its position in Ligand Pharmaceuticals by 4.1% in the 4th quarter. Trillium Asset Management LLC now owns 4,386 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 171 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Ligand Pharmaceuticals by 33.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 713 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 180 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in Ligand Pharmaceuticals by 4.4% in the 4th quarter. Tocqueville Asset Management L.P. now owns 4,571 shares of the biotechnology company’s stock worth $620,000 after purchasing an additional 193 shares during the last quarter. Finally, LS Investment Advisors LLC grew its position in Ligand Pharmaceuticals by 17.4% in the 4th quarter. LS Investment Advisors LLC now owns 1,606 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 238 shares during the last quarter.
Ligand Pharmaceuticals stock opened at $120.61 on Wednesday. The company has a quick ratio of 10.50, a current ratio of 10.59 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $2.61 billion, a PE ratio of 19.21, a P/E/G ratio of 1.14 and a beta of 1.40. Ligand Pharmaceuticals Inc. has a 12-month low of $98.56 and a 12-month high of $278.62.
Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.48. The business had revenue of $59.59 million during the quarter, compared to analysts’ expectations of $52.58 million. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The business’s revenue was up 18.1% on a year-over-year basis. During the same period last year, the firm posted $1.31 earnings per share. As a group, sell-side analysts anticipate that Ligand Pharmaceuticals Inc. will post 5.23 EPS for the current fiscal year.
LGND has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 15th. HC Wainwright set a $281.00 target price on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 19th. ValuEngine upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. TheStreet cut shares of Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, January 2nd. Finally, Argus restated a “buy” rating and issued a $150.00 target price (down previously from $200.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, February 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $216.57.
TRADEMARK VIOLATION NOTICE: “Bellevue Group AG Acquires 12,600 Shares of Ligand Pharmaceuticals Inc. (LGND)” was originally published by Zolmax and is owned by of Zolmax. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://zolmax.com/investing/bellevue-group-ag-acquires-12600-shares-of-ligand-pharmaceuticals-inc-lgnd/2941799.html.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Further Reading: Balance Sheet
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.